Alexander Ochman, DO
Interventional Cardiology · Bend, ORNPI 1316392970
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Biotronik Inc. at 38.0% of the total. 2025 is the largest year on record at $2,740, more than ten times the $71 reported in 2019.
Across 93 payments — averaging $64.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$2K
- Boston Scientific$1K
- Abbott$847
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$259
- Amgen$201
- Atricure, Inc.$175
- plus $777 from 11 others
What the payments were for
- Travel & lodging$2,40140%
- Food & beverage$3,16252%
- Education$4628%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 16 | $2,287 |
| Boston Scientific | 25 | $1,479 |
| Abbott | 17 | $847 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $259 |
| Amgen | 2 | $201 |
| Atricure, Inc. | 2 | $175 |
| Medtronic | 5 | $154 |
| Novartis | 6 | $146 |
| Artivion, Inc. | 1 | $114 |
| Abiomed | 1 | $107 |
| Impulse Dynamics (USA) Inc. | 3 | $78 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Novo Nordisk | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 1 | $35 |
| AstraZeneca | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solia$1,084
- Selectra$1,084
- EMBLEM MRI S-ICD$806
- HeartMate 3 Left Ventricular Assist Device$196
- WATCHMAN Access System$121
- Confirm Rx$115
- Cardiac non-SynerGraft$114
- CRYOVALVE SG PULMONARY HUMAN HEART VALVE$114
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$114
- BIOGLUE SURGICAL ADHESIVE$114
- PHOTOFIX DECELLULARIZED BOVINE PERICARDIUM$114
- ATTAIN COMMAND + SUREVALVE$109
- Impella$107
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$104
- ATRICLIP LAA EXCLUSION SYSTEM$104
- AVEIR$103
- QUADRA ASSURA$102
How this compares
$6,025 in reported general payments places this provider in the 55th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $221,022 |
| Repatha SureclickEvolocumab | 77 | $99,343 |
| JardianceEmpagliflozin | 38 | $52,729 |
| EntrestoSacubitril/Valsartan | 22 | $35,221 |
| XareltoRivaroxaban | 24 | $34,635 |
| Praluent PenAlirocumab | 13 | $10,581 |
| Rosuvastatin Calcium | 319 | $8,919 |
| Metoprolol Succinate | 361 | $6,078 |
| Ranolazine ErRanolazine | 52 | $2,725 |
| Ezetimibe | 79 | $2,381 |
| Atorvastatin Calcium | 154 | $2,136 |
| Spironolactone | 200 | $1,498 |
| Losartan Potassium | 122 | $1,462 |
| Potassium Chloride | 65 | $1,448 |
| Flecainide Acetate | 24 | $1,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $146 | $35,22122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Bend
- Saurabh GuptaBend$550K
- Erinn HughesBend$14K
- Nicholas BussBend$7K
- Michael SultanBend$5K
- Bruce McLellanBend$4K
- Allen RafaelBend$3K
- Michael WidmerBend$2K
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.